<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00479882</url>
  </required_header>
  <id_info>
    <org_study_id>0524B-063</org_study_id>
    <secondary_id>MK-0524B-063</secondary_id>
    <secondary_id>2007_504</secondary_id>
    <nct_id>NCT00479882</nct_id>
  </id_info>
  <brief_title>MK-0524B Lipid Study (MK-0524B-063)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, &quot;Crossover&quot; Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK-0524A + Simvastatin Coadministration in Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 20-week clinical trial in participants with primary hypercholesterolemia or mixed
      dyslipidemia to demonstrate the effect of MK-0524B compared to MK-0524A + Simvastatin on
      lipid values.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period (Week 12 for Period II and Week 20 for Period III)</time_frame>
    <description>Blood samples taken at baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period to determine the LDL-C levels. The change from baseline after 8 weeks of treatment was recorded.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period (Week 12 for Period II and Week 20 for Period III)</time_frame>
    <description>Blood samples taken at baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period to determine the HDL-C levels. The change from baseline after 8 weeks of treatment was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of &gt;=3 x Upper Limit of Normal (ULN)</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>Participants had AST and ALT levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of either AST or ALT that was 3 x ULN or greater were recorded. The AST ULNs for males and females were 43 U/L and 36 U/L, respectively. The ALT ULNs for males and females were 40 U/L and 33 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Creatine Kinase (CK) &gt;=10 x ULN</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater and had associated muscle symptoms present within +/- 7 days were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms - Drug Related</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly related to study drug were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>Participants had fasting glucose levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had the new diagnosis of impaired fasting blood glucose were recorded. A pre-defined set of MedDRA terms was used to identify participants whose glycemic status became 'impaired' during the course of treatment (from clinical adverse experience reports). The MedDRA terms were as follows: blood glucose increased, blood glucose abnormal, glucose tolerance decreased, glucose tolerance test abnormal, carbohydrate tolerance decreased, glucose tolerance impaired, hyperglycaemia, impaired fasting glucose, impaired insulin secretion, metabolic syndrome, insulin resistance, insulin resistance syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With New Diagnosis of Diabetes</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an adverse Event (AE) related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Worsening of the Pre-existing Conditions of Diabetes in Participants With Diabetes at Baseline</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>Participants with diabetes at baseline and who experienced a worsening of the diabetes identified through adverse event reports using a pre-defined set of terms and/or increasing dose/adding a new anti-diabetic medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee as cardiovascular events were recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Laboratory AE</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. Participants who were discontinued from the study due to a clinical AE were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants who were discontinued from the study due to a laboratory AE were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Hepatitis-related Non-serious Clinical AE</measure>
    <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
    <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Non-serious Hepatitis-related AEs were identified by a collective review using the following pre-specified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in LDL-C at Week 4</measure>
    <time_frame>Baseline (Day1 of Period I) and Week 4</time_frame>
    <description>Blood samples taken at baseline (Day1 of Period I) and after 4 weeks of treatment to determine the LDL-C levels. The change from baseline after 4 weeks of treatment was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in HDL-C at Week 4</measure>
    <time_frame>Baseline (Day1 of Period I) and Week 4</time_frame>
    <description>Blood samples taken at baseline (Day1 of Period I) and after 4 weeks of treatment to determine the HDL-C levels. The change from baseline after 4 weeks of treatment was recorded.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2414</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: simvastatin</intervention_name>
    <arm_group_label>Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg</arm_group_label>
    <arm_group_label>Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg</arm_group_label>
    <arm_group_label>Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg</arm_group_label>
    <arm_group_label>Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg</arm_group_label>
    <other_name>Zocor®</other_name>
    <other_name>MK0733</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0524A</intervention_name>
    <description>Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet</description>
    <arm_group_label>Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg</arm_group_label>
    <arm_group_label>Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg</arm_group_label>
    <arm_group_label>Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg</arm_group_label>
    <arm_group_label>Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg</arm_group_label>
    <arm_group_label>Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg</arm_group_label>
    <arm_group_label>Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg</arm_group_label>
    <arm_group_label>Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0524B</intervention_name>
    <arm_group_label>Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg</arm_group_label>
    <arm_group_label>Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg</arm_group_label>
    <arm_group_label>Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg</arm_group_label>
    <arm_group_label>Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has primary hypercholesterolemia or mixed dyslipidemia based on medical history
             (previous diagnosis), historic lipid values, or as otherwise determined through
             optional lipid measurements at screening visit

          -  meets one of the following triglyceride (TG) criteria:

               1. is on niacin, statin, or fibrate and has TG &lt;500 mg/dL at or within 6 months of
                  washout

               2. is not on any lipid altering therapy or is on lipid altering therapy other than
                  niacin, statin, or fibrate and has TG &lt;600 mg/dL at or within 6 months of
                  screening

        Exclusion Criteria:

          -  is high risk (coronary heart disease [CHD] or CHD risk equivalent) AND is on a statin

          -  is pregnant or breast-feeding, or expecting to conceive during the study including the
             14-day post study follow-up

          -  has Type 1 or Type 2 diabetes mellitus and is on statin therapy, is poorly controlled,
             is newly diagnosed (within 3 months of Visit 1), has recently experienced repeated
             hypoglycemia or unstable glycemic control or is taking new or recently adjusted
             anti-diabetic medications (with the exception of +/- 10 units of insulin) within 3
             months of Visit 1

          -  has the following conditions: chronic heart failure, uncontrolled/unstable cardiac
             arrhythmias, unstable hypertension, active or chronic hepatobiliary disorder or
             hepatic disease, human immunodeficiency virus (HIV) positive, gout (within 1 year)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>(MedWatch - FDA maintained medical product safety Information)</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>(Merck: Patient &amp; Caregiver U.S. Product Web Site)</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2007</study_first_submitted>
  <study_first_submitted_qc>May 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2007</study_first_posted>
  <results_first_submitted>December 16, 2015</results_first_submitted>
  <results_first_submitted_qc>March 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2016</results_first_posted>
  <last_update_submitted>March 3, 2017</last_update_submitted>
  <last_update_submitted_qc>March 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis Link</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/study.html?id=0524B-063&amp;kw=0524B-063&amp;tab=access</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants completed a 6-8 week washout then completed a 2-week placebo run-in prior to the start of active treatment. Includes 6 participants who had an adverse event that began during the placebo run-in but did not lead to discontinuation until after randomization in Period I or II.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg</title>
          <description>After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg</title>
          <description>After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg</title>
          <description>After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg</title>
          <description>After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Precrossover: Periods I/II (Weeks 1-12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="610"/>
                <participants group_id="P2" count="602"/>
                <participants group_id="P3" count="597"/>
                <participants group_id="P4" count="605"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="472"/>
                <participants group_id="P2" count="440"/>
                <participants group_id="P3" count="440"/>
                <participants group_id="P4" count="465"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="138"/>
                <participants group_id="P2" count="162"/>
                <participants group_id="P3" count="157"/>
                <participants group_id="P4" count="140"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Clinical Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="98"/>
                <participants group_id="P4" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Crossover: Period III (Weeks 13-20)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="472"/>
                <participants group_id="P2" count="440"/>
                <participants group_id="P3" count="440"/>
                <participants group_id="P4" count="465"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="447"/>
                <participants group_id="P2" count="419"/>
                <participants group_id="P3" count="420"/>
                <participants group_id="P4" count="447"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Clinical Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1: MK-0524B 1.8g/20mg→MK-0524A 2g+Simvastatin 20mg</title>
          <description>After a 2-week placebo run-in, participants will receive MK-0524B (0.9 g/simvastatin 10 mg) for 4 weeks, then MK-0524B 1.8g /20 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 20 mg for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg →MK-0524B 1.8g/20mg</title>
          <description>After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 10 mg for 4 weeks, then co-administered MK-0524A 2g +simvastatin 20 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/20 mg combination tablet for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3: MK-0524B 1.8g/40mg→MK-0524A 2g+Simvastatin 40mg</title>
          <description>After a 2-week placebo run-in, participants will receive MK-0524B 0.9g/40 mg combination tablet for 4 weeks, then MK-0524B 1.8g /40 mg combination tablet for 8 weeks. Participant is then co-administered MK-0524A 2 g + simvastatin 40 mg for 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg →MK-0524B 1.8g/40mg</title>
          <description>After a 2-week placebo run-in, participants will be co-administered MK-0524A 1g + simvastatin 40 mg for 4 weeks, then co-administration MK-0524A 2g +simvastatin 40 mg for 8 weeks. Participant then receives MK-0524B 1.8 g/40 mg combination tablet for 8 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="610"/>
            <count group_id="B2" value="602"/>
            <count group_id="B3" value="597"/>
            <count group_id="B4" value="605"/>
            <count group_id="B5" value="2414"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="491"/>
                    <measurement group_id="B2" value="470"/>
                    <measurement group_id="B3" value="468"/>
                    <measurement group_id="B4" value="477"/>
                    <measurement group_id="B5" value="1906"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="128"/>
                    <measurement group_id="B5" value="508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="334"/>
                    <measurement group_id="B3" value="313"/>
                    <measurement group_id="B4" value="316"/>
                    <measurement group_id="B5" value="1288"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="268"/>
                    <measurement group_id="B3" value="284"/>
                    <measurement group_id="B4" value="289"/>
                    <measurement group_id="B5" value="1126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</title>
        <description>Blood samples taken at baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period to determine the LDL-C levels. The change from baseline after 8 weeks of treatment was recorded.</description>
        <time_frame>Baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period (Week 12 for Period II and Week 20 for Period III)</time_frame>
        <population>Participants who completed the study and had respective endpoint data available at baseline and end of each treatment period. End of period value was defined as measurements collected on the same date as the corresponding end of period visit date. Results were reported by dose of study drug taken and not by randomly assigned sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg for 8 weeks in either Period II or Period III regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O2">
            <title>MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 2g+Simvastatin 20mg for 8 weeks in either Period II or Period III regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O3">
            <title>MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg for 8 weeks in either Period II or Period III treatment period regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O4">
            <title>MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 2g+Simvastatin 40mg for 8 weeks in either Period II or Period III regardless of randomly assigned sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)</title>
          <description>Blood samples taken at baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period to determine the LDL-C levels. The change from baseline after 8 weeks of treatment was recorded.</description>
          <population>Participants who completed the study and had respective endpoint data available at baseline and end of each treatment period. End of period value was defined as measurements collected on the same date as the corresponding end of period visit date. Results were reported by dose of study drug taken and not by randomly assigned sequence.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="844"/>
                <count group_id="O2" value="844"/>
                <count group_id="O3" value="843"/>
                <count group_id="O4" value="843"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.6" lower_limit="-45.3" upper_limit="-43.8"/>
                    <measurement group_id="O2" value="-46.9" lower_limit="-47.7" upper_limit="-46.2"/>
                    <measurement group_id="O3" value="-48.9" lower_limit="-49.7" upper_limit="-48.2"/>
                    <measurement group_id="O4" value="-50.4" lower_limit="-51.1" upper_limit="-49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Clinical equivalence LDL-C reduction was established if the 95% CI for the difference between these two treatments in percent change from baseline in LDL-C fell within ±3%.</non_inferiority_desc>
            <param_type>Difference in Least squares mean</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Clinical equivalence LDL-C reduction was established if the 95% CI for the difference between these two treatments in percent change from baseline in LDL-C fell within ±3%.</non_inferiority_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</title>
        <description>Blood samples taken at baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period to determine the HDL-C levels. The change from baseline after 8 weeks of treatment was recorded.</description>
        <time_frame>Baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period (Week 12 for Period II and Week 20 for Period III)</time_frame>
        <population>Participants who completed the study and had respective endpoint data available at baseline and end of each treatment period. End of period value was defined as measurements collected on the same date as the corresponding end of period visit date. Results were reported by dose of study drug taken and not by randomly assigned sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg for 8 weeks in either Period II or Period III regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O2">
            <title>MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 2g+Simvastatin 20mg for 8 weeks in either Period II or Period III regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O3">
            <title>MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg for 8 weeks in either Period II or Period III treatment period regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O4">
            <title>MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 2g+Simvastatin 40mg for 8 weeks in either Period II or Period III regardless of randomly assigned sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)</title>
          <description>Blood samples taken at baseline (Week 4 for Period II; Week 12 for Period III) and after 8 weeks of treatment during each period to determine the HDL-C levels. The change from baseline after 8 weeks of treatment was recorded.</description>
          <population>Participants who completed the study and had respective endpoint data available at baseline and end of each treatment period. End of period value was defined as measurements collected on the same date as the corresponding end of period visit date. Results were reported by dose of study drug taken and not by randomly assigned sequence.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="845"/>
                <count group_id="O2" value="845"/>
                <count group_id="O3" value="845"/>
                <count group_id="O4" value="845"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="26.5" upper_limit="28.2"/>
                    <measurement group_id="O2" value="27.6" lower_limit="26.7" upper_limit="28.4"/>
                    <measurement group_id="O3" value="27.7" lower_limit="26.9" upper_limit="28.4"/>
                    <measurement group_id="O4" value="28.5" lower_limit="27.8" upper_limit="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Clinical equivalence HDL-C reduction was established if the 95% CI for the difference between these two treatments in percent change from baseline in LDL-C fell within ±4%.</non_inferiority_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Clinical equivalence HDL-C reduction was established if the 95% CI for the difference between these two treatments in percent change from baseline in LDL-C fell within ±4%.</non_inferiority_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of &gt;=3 x Upper Limit of Normal (ULN)</title>
        <description>Participants had AST and ALT levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of either AST or ALT that was 3 x ULN or greater were recorded. The AST ULNs for males and females were 43 U/L and 36 U/L, respectively. The ALT ULNs for males and females were 40 U/L and 33 U/L, respectively.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of &gt;=3 x Upper Limit of Normal (ULN)</title>
          <description>Participants had AST and ALT levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of either AST or ALT that was 3 x ULN or greater were recorded. The AST ULNs for males and females were 43 U/L and 36 U/L, respectively. The ALT ULNs for males and females were 40 U/L and 33 U/L, respectively.</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="580"/>
                <count group_id="O3" value="469"/>
                <count group_id="O4" value="437"/>
                <count group_id="O5" value="568"/>
                <count group_id="O6" value="592"/>
                <count group_id="O7" value="438"/>
                <count group_id="O8" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.5"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0.9"/>
                    <measurement group_id="O5" value="0.7"/>
                    <measurement group_id="O6" value="1.0"/>
                    <measurement group_id="O7" value="0.5"/>
                    <measurement group_id="O8" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.753</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Creatine Kinase (CK) &gt;=10 x ULN</title>
        <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Creatine Kinase (CK) &gt;=10 x ULN</title>
          <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="580"/>
                <count group_id="O3" value="469"/>
                <count group_id="O4" value="437"/>
                <count group_id="O5" value="568"/>
                <count group_id="O6" value="592"/>
                <count group_id="O7" value="438"/>
                <count group_id="O8" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.4"/>
                    <measurement group_id="O6" value="0.2"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.617</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms</title>
        <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater and had associated muscle symptoms present within +/- 7 days were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms</title>
          <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater and had associated muscle symptoms present within +/- 7 days were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="580"/>
                <count group_id="O3" value="469"/>
                <count group_id="O4" value="437"/>
                <count group_id="O5" value="568"/>
                <count group_id="O6" value="592"/>
                <count group_id="O7" value="438"/>
                <count group_id="O8" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms - Drug Related</title>
        <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly related to study drug were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With CK &gt;=10 x ULN With Muscle Symptoms - Drug Related</title>
          <description>Participants had CK levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had an assessment of CK that was 10 x ULN or greater and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly related to study drug were recorded. The ULNs for males and females were 207 U/L and 169 U/L, respectively.</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="588"/>
                <count group_id="O2" value="580"/>
                <count group_id="O3" value="469"/>
                <count group_id="O4" value="437"/>
                <count group_id="O5" value="568"/>
                <count group_id="O6" value="592"/>
                <count group_id="O7" value="438"/>
                <count group_id="O8" value="464"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose</title>
        <description>Participants had fasting glucose levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had the new diagnosis of impaired fasting blood glucose were recorded. A pre-defined set of MedDRA terms was used to identify participants whose glycemic status became ‘impaired’ during the course of treatment (from clinical adverse experience reports). The MedDRA terms were as follows: blood glucose increased, blood glucose abnormal, glucose tolerance decreased, glucose tolerance test abnormal, carbohydrate tolerance decreased, glucose tolerance impaired, hyperglycaemia, impaired fasting glucose, impaired insulin secretion, metabolic syndrome, insulin resistance, insulin resistance syndrome.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who had normal fasting blood glucose levels at baseline and who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose</title>
          <description>Participants had fasting glucose levels assessed during Period I (4 weeks ) throughout each 8 week treatment period (20 weeks total). Participants who had the new diagnosis of impaired fasting blood glucose were recorded. A pre-defined set of MedDRA terms was used to identify participants whose glycemic status became ‘impaired’ during the course of treatment (from clinical adverse experience reports). The MedDRA terms were as follows: blood glucose increased, blood glucose abnormal, glucose tolerance decreased, glucose tolerance test abnormal, carbohydrate tolerance decreased, glucose tolerance impaired, hyperglycaemia, impaired fasting glucose, impaired insulin secretion, metabolic syndrome, insulin resistance, insulin resistance syndrome.</description>
          <population>All participants who had normal fasting blood glucose levels at baseline and who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="484"/>
                <count group_id="O2" value="473"/>
                <count group_id="O3" value="468"/>
                <count group_id="O4" value="483"/>
                <count group_id="O5" value="365"/>
                <count group_id="O6" value="343"/>
                <count group_id="O7" value="345"/>
                <count group_id="O8" value="372"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.2"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.497</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With New Diagnosis of Diabetes</title>
        <description>Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an adverse Event (AE) related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants without diabetes at baseline and who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With New Diagnosis of Diabetes</title>
          <description>Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an adverse Event (AE) related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults.</description>
          <population>All participants without diabetes at baseline and who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="554"/>
                <count group_id="O2" value="551"/>
                <count group_id="O3" value="427"/>
                <count group_id="O4" value="404"/>
                <count group_id="O5" value="545"/>
                <count group_id="O6" value="545"/>
                <count group_id="O7" value="404"/>
                <count group_id="O8" value="422"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.5"/>
                    <measurement group_id="O4" value="0.7"/>
                    <measurement group_id="O5" value="0.6"/>
                    <measurement group_id="O6" value="0.4"/>
                    <measurement group_id="O7" value="0.7"/>
                    <measurement group_id="O8" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.4</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Period I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Worsening of the Pre-existing Conditions of Diabetes in Participants With Diabetes at Baseline</title>
        <description>Participants with diabetes at baseline and who experienced a worsening of the diabetes identified through adverse event reports using a pre-defined set of terms and/or increasing dose/adding a new anti-diabetic medication.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants with diabetes at baseline and who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Worsening of the Pre-existing Conditions of Diabetes in Participants With Diabetes at Baseline</title>
          <description>Participants with diabetes at baseline and who experienced a worsening of the diabetes identified through adverse event reports using a pre-defined set of terms and/or increasing dose/adding a new anti-diabetic medication.</description>
          <population>All participants with diabetes at baseline and who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="36"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="60"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8"/>
                    <measurement group_id="O2" value="15.7"/>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="8.3"/>
                    <measurement group_id="O5" value="3.8"/>
                    <measurement group_id="O6" value="8.3"/>
                    <measurement group_id="O7" value="8.3"/>
                    <measurement group_id="O8" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.452</p_value>
            <method>Fisher Exact</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event</title>
        <description>Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee as cardiovascular events were recorded</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event</title>
          <description>Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee as cardiovascular events were recorded</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="602"/>
                <count group_id="O3" value="472"/>
                <count group_id="O4" value="440"/>
                <count group_id="O5" value="597"/>
                <count group_id="O6" value="605"/>
                <count group_id="O7" value="440"/>
                <count group_id="O8" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.2"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.2"/>
                    <measurement group_id="O6" value="0.0"/>
                    <measurement group_id="O7" value="0.2"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
            <estimate_desc>Wilson's Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant.</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="602"/>
                <count group_id="O3" value="472"/>
                <count group_id="O4" value="440"/>
                <count group_id="O5" value="597"/>
                <count group_id="O6" value="605"/>
                <count group_id="O7" value="440"/>
                <count group_id="O8" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5"/>
                    <measurement group_id="O2" value="68.9"/>
                    <measurement group_id="O3" value="35.6"/>
                    <measurement group_id="O4" value="37.5"/>
                    <measurement group_id="O5" value="67.5"/>
                    <measurement group_id="O6" value="67.4"/>
                    <measurement group_id="O7" value="32.3"/>
                    <measurement group_id="O8" value="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>3.8</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.9</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience at Least 1 Laboratory AE</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least 1 Laboratory AE</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="602"/>
                <count group_id="O3" value="472"/>
                <count group_id="O4" value="440"/>
                <count group_id="O5" value="597"/>
                <count group_id="O6" value="605"/>
                <count group_id="O7" value="440"/>
                <count group_id="O8" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="4.2"/>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="3.6"/>
                    <measurement group_id="O5" value="6.2"/>
                    <measurement group_id="O6" value="4.6"/>
                    <measurement group_id="O7" value="5.9"/>
                    <measurement group_id="O8" value="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>2.1</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>2.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>5.2</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Period III</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>2.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.8</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. Participants who were discontinued from the study due to a clinical AE were recorded.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined, where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover). Excludes 6 participants who had an AE that began during the placebo run-in.</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. Participants who were discontinued from the study due to a clinical AE were recorded.</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined, where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover). Excludes 6 participants who had an AE that began during the placebo run-in.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="602"/>
                <count group_id="O3" value="472"/>
                <count group_id="O4" value="440"/>
                <count group_id="O5" value="597"/>
                <count group_id="O6" value="605"/>
                <count group_id="O7" value="440"/>
                <count group_id="O8" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9"/>
                    <measurement group_id="O2" value="15.9"/>
                    <measurement group_id="O3" value="1.9"/>
                    <measurement group_id="O4" value="2.7"/>
                    <measurement group_id="O5" value="16.4"/>
                    <measurement group_id="O6" value="14.4"/>
                    <measurement group_id="O7" value="2.5"/>
                    <measurement group_id="O8" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants who were discontinued from the study due to a laboratory AE were recorded.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants who were discontinued from the study due to a laboratory AE were recorded.</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="602"/>
                <count group_id="O3" value="472"/>
                <count group_id="O4" value="440"/>
                <count group_id="O5" value="597"/>
                <count group_id="O6" value="605"/>
                <count group_id="O7" value="440"/>
                <count group_id="O8" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.7"/>
                    <measurement group_id="O3" value="0.6"/>
                    <measurement group_id="O4" value="0.2"/>
                    <measurement group_id="O5" value="0.7"/>
                    <measurement group_id="O6" value="0.8"/>
                    <measurement group_id="O7" value="0.5"/>
                    <measurement group_id="O8" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experience at Least 1 Hepatitis-related Non-serious Clinical AE</title>
        <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Non-serious Hepatitis-related AEs were identified by a collective review using the following pre-specified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury.</description>
        <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
        <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
        <group_list>
          <group group_id="O1">
            <title>Sequence 1: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
          </group>
          <group group_id="O2">
            <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Periods I/II.</description>
          </group>
          <group group_id="O3">
            <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 20mg and MK-0524A 2g+ Simvastatin 20mg during Period III</description>
          </group>
          <group group_id="O4">
            <title>Sequence 2: MK-0524B 1.8g/20mg</title>
            <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
          </group>
          <group group_id="O5">
            <title>Sequence 3: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
          </group>
          <group group_id="O6">
            <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II.</description>
          </group>
          <group group_id="O7">
            <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
            <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
          </group>
          <group group_id="O8">
            <title>Sequence 4: MK-0524B 1.8g/40mg</title>
            <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least 1 Hepatitis-related Non-serious Clinical AE</title>
          <description>An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Non-serious Hepatitis-related AEs were identified by a collective review using the following pre-specified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury.</description>
          <population>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="610"/>
                <count group_id="O2" value="602"/>
                <count group_id="O3" value="472"/>
                <count group_id="O4" value="440"/>
                <count group_id="O5" value="597"/>
                <count group_id="O6" value="605"/>
                <count group_id="O7" value="440"/>
                <count group_id="O8" value="465"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                    <measurement group_id="O6" value="0.2"/>
                    <measurement group_id="O7" value="0.0"/>
                    <measurement group_id="O8" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Periods I/II</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
            <estimate_desc>Wilson’s Score Method</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in LDL-C at Week 4</title>
        <description>Blood samples taken at baseline (Day1 of Period I) and after 4 weeks of treatment to determine the LDL-C levels. The change from baseline after 4 weeks of treatment was recorded.</description>
        <time_frame>Baseline (Day1 of Period I) and Week 4</time_frame>
        <population>Participants that completed the study and had respective endpoint data available at baseline and end of each treatment period. End of period value was defined as measurements collected on the same date as the corresponding end of period visit date. Results were reported by dose of study drug taken and not by randomly assigned sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 0.9g/10mg</title>
            <description>Participants who received MK-0524B 0.9g/10mg for 4 weeks in Period I regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O2">
            <title>MK-0524A 1g+Simvastatin 10mg</title>
            <description>Participants who received MK-0524A 1g+Simvastatin 10mg for 4 weeks in Period I regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O3">
            <title>MK-0524B 0.9 g/40 mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg for 4 weeks in Period I regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O4">
            <title>MK-0524A 1 g + Simvastatin 40 mg</title>
            <description>Participants who received MK-0524A 1g+Simvastatin 40mg for 4 weeks in Period I regardless of randomly assigned sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in LDL-C at Week 4</title>
          <description>Blood samples taken at baseline (Day1 of Period I) and after 4 weeks of treatment to determine the LDL-C levels. The change from baseline after 4 weeks of treatment was recorded.</description>
          <population>Participants that completed the study and had respective endpoint data available at baseline and end of each treatment period. End of period value was defined as measurements collected on the same date as the corresponding end of period visit date. Results were reported by dose of study drug taken and not by randomly assigned sequence.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="582"/>
                <count group_id="O2" value="574"/>
                <count group_id="O3" value="556"/>
                <count group_id="O4" value="581"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34.8" lower_limit="-36.6" upper_limit="-33.0"/>
                    <measurement group_id="O2" value="-35.8" lower_limit="-37.6" upper_limit="-34.0"/>
                    <measurement group_id="O3" value="-42.2" lower_limit="-44.3" upper_limit="-40.0"/>
                    <measurement group_id="O4" value="-45.8" lower_limit="-48.0" upper_limit="-43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.341</p_value>
            <method>ANOVA</method>
            <method_desc>Factors for treatment, country and gender</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANOVA</method>
            <method_desc>Factors for treatment, country and gender.</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>6.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in HDL-C at Week 4</title>
        <description>Blood samples taken at baseline (Day1 of Period I) and after 4 weeks of treatment to determine the HDL-C levels. The change from baseline after 4 weeks of treatment was recorded.</description>
        <time_frame>Baseline (Day1 of Period I) and Week 4</time_frame>
        <population>Participants that completed the study and had respective endpoint data available at baseline and end of each treatment period. End of period value was defined as measurements collected on the same date as the corresponding end of period visit date. Results were reported by dose of study drug taken and not by randomly assigned sequence.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0524B 0.9g/10mg</title>
            <description>Participants who received MK-0524B 0.9g/10mg for 4 weeks in Period I regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O2">
            <title>MK-0524A 1g+Simvastatin 10mg</title>
            <description>Participants who received MK-0524A 1g+Simvastatin 10mg for 4 weeks in Period I regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O3">
            <title>MK-0524B 0.9 g/40 mg</title>
            <description>Participants who received MK-0524B 0.9g/40mg for 4 weeks in Period I regardless of randomly assigned sequence.</description>
          </group>
          <group group_id="O4">
            <title>MK-0524A 1 g + Simvastatin 40 mg</title>
            <description>Participants who received MK-0524A 1g+Simvastatin 40mg for 4 weeks in Period I regardless of randomly assigned sequence.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in HDL-C at Week 4</title>
          <description>Blood samples taken at baseline (Day1 of Period I) and after 4 weeks of treatment to determine the HDL-C levels. The change from baseline after 4 weeks of treatment was recorded.</description>
          <population>Participants that completed the study and had respective endpoint data available at baseline and end of each treatment period. End of period value was defined as measurements collected on the same date as the corresponding end of period visit date. Results were reported by dose of study drug taken and not by randomly assigned sequence.</population>
          <units>Percentage Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="582"/>
                <count group_id="O2" value="575"/>
                <count group_id="O3" value="555"/>
                <count group_id="O4" value="583"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.3" lower_limit="16.6" upper_limit="19.9"/>
                    <measurement group_id="O2" value="18.7" lower_limit="17.0" upper_limit="20.3"/>
                    <measurement group_id="O3" value="19.8" lower_limit="17.9" upper_limit="21.6"/>
                    <measurement group_id="O4" value="19.6" lower_limit="17.8" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.690</p_value>
            <method>ANOVA</method>
            <method_desc>Factors for treatment, country and gender</method_desc>
            <param_type>Difference in Least Squares Mean</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.3</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.879</p_value>
            <method>ANOVA</method>
            <method_desc>Factors for treatment, country and gender</method_desc>
            <param_type>Difference in Least Squares Means</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up 20 weeks (12 weeks in Period I/II and 8 weeks in Period III)</time_frame>
      <desc>All participants who received at least 1 dose of study drug. Safety analysis was based on the experiences accumulated during Periods I/II combined (pre-crossover), where the study follows a parallel design. A separate safety analysis was performed for Period III (post-crossover).</desc>
      <group_list>
        <group group_id="E1">
          <title>Sequence 1: MK-0524B 1.8g/20mg</title>
          <description>Participants who received MK-0524B 0.9g/20mg and MK-0524B 1.8g/20mg during Periods I/II</description>
        </group>
        <group group_id="E2">
          <title>Sequence 2: MK-0524A 2g+Simvastatin 20mg</title>
          <description>Participants who received MK-0524B 1g + Simvastatin 20mg and MK-0524B 2g+ Simvastatin 20mg during Periods I/II</description>
        </group>
        <group group_id="E3">
          <title>Sequence 1: MK-0524A 2g+Simvastatin 20mg</title>
          <description>Participants who received MK-0524B 1g + Simvastatin 20mg and MK-0524B 2g+ Simvastatin 20mg during Period III</description>
        </group>
        <group group_id="E4">
          <title>Sequence 2: MK-0524B 1.8g/20mg</title>
          <description>Participants who received MK-0524B 1.8g/20mg during Periods III</description>
        </group>
        <group group_id="E5">
          <title>Sequence 3: MK-0524B 1.8g/40mg</title>
          <description>Participants who received MK-0524B 0.9g/40mg and MK-0524B 1.8g/40mg during Periods I/II</description>
        </group>
        <group group_id="E6">
          <title>Sequence 4: MK-0524A 2g+Simvastatin 40mg</title>
          <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Periods I/II</description>
        </group>
        <group group_id="E7">
          <title>Sequence 3: MK-0524A 2g+Simvastatin 40mg</title>
          <description>Participants who received MK-0524A 1g + Simvastatin 40mg and MK-0524A 2g+ Simvastatin 40mg during Period III</description>
        </group>
        <group group_id="E8">
          <title>Sequence 4: MK-0524B 1.8g/40mg</title>
          <description>Participants who received MK-0524B 1.8g/40mg during Periods III</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="602"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="440"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="597"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="605"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="440"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Device migration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Pharyngeal neoplasm benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Choking</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="610"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="602"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="597"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="605"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="440"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="225" subjects_at_risk="610"/>
                <counts group_id="E2" subjects_affected="227" subjects_at_risk="602"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="472"/>
                <counts group_id="E4" subjects_affected="48" subjects_at_risk="440"/>
                <counts group_id="E5" subjects_affected="222" subjects_at_risk="597"/>
                <counts group_id="E6" subjects_affected="237" subjects_at_risk="605"/>
                <counts group_id="E7" subjects_affected="31" subjects_at_risk="440"/>
                <counts group_id="E8" subjects_affected="45" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="610"/>
                <counts group_id="E2" events="41" subjects_affected="33" subjects_at_risk="602"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="472"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="440"/>
                <counts group_id="E5" events="29" subjects_affected="27" subjects_at_risk="597"/>
                <counts group_id="E6" events="39" subjects_affected="37" subjects_at_risk="605"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="440"/>
                <counts group_id="E8" events="15" subjects_affected="13" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="610"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="602"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="472"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="440"/>
                <counts group_id="E5" events="25" subjects_affected="24" subjects_at_risk="597"/>
                <counts group_id="E6" events="31" subjects_affected="28" subjects_at_risk="605"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="440"/>
                <counts group_id="E8" events="9" subjects_affected="8" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="79" subjects_affected="67" subjects_at_risk="610"/>
                <counts group_id="E2" events="84" subjects_affected="72" subjects_at_risk="602"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="472"/>
                <counts group_id="E4" events="17" subjects_affected="15" subjects_at_risk="440"/>
                <counts group_id="E5" events="54" subjects_affected="50" subjects_at_risk="597"/>
                <counts group_id="E6" events="93" subjects_affected="75" subjects_at_risk="605"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="440"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="189" subjects_affected="155" subjects_at_risk="610"/>
                <counts group_id="E2" events="166" subjects_affected="132" subjects_at_risk="602"/>
                <counts group_id="E3" events="34" subjects_affected="23" subjects_at_risk="472"/>
                <counts group_id="E4" events="20" subjects_affected="15" subjects_at_risk="440"/>
                <counts group_id="E5" events="189" subjects_affected="162" subjects_at_risk="597"/>
                <counts group_id="E6" events="179" subjects_affected="151" subjects_at_risk="605"/>
                <counts group_id="E7" events="15" subjects_affected="14" subjects_at_risk="440"/>
                <counts group_id="E8" events="23" subjects_affected="19" subjects_at_risk="465"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission. Sponsor review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

